Stentless mitral valve replacement using autologous pericardium study
Not Applicable
- Conditions
- Mitral regurgitation
- Registration Number
- JPRN-UMIN000012659
- Lead Sponsor
- Sakakibara Heart Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. Active malignancy except for in situ cancer 2. Dialysis 3. Participating in other trials 4. Myocardial infarction in the last 6 months 5. Stroke in the last 6 months 6. Previous percutaneous coronary stenting in a month before surgery 7. Concomitant procedures other than tricuspid valve repair, maze operation and pulmonary vein isolation. 8. Severe left ventricular dysfunction (ejection fraction less than 0.30) 9. When excellent outcomes and prognosis are expected with standard prosthetic mitral valve replacement 10. When a principal investigator deems a patient inappropriate as a trial subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Residual mitral regurgitation two weeks after surgery
- Secondary Outcome Measures
Name Time Method Residual and recurrent mitral regurgitation 12 months after surgery, adverse events in 12 months after surgery, and adverse events in 60 months after surgery.